Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in Low or Int-1 Risk MDS and CMML
NCT04239157Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2020
- Primary completion
- Dec 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of canakinumab in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), clonal cytopenia of undetermined significance (CCUS), sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2020; status: recruiting.
02
Drugs
canakinumab
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)clonal cytopenia of undetermined significance (CCUS)
Beyond the preview
Go deeper on NCT04239157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04239157.